In patients with tuberous sclerosis complex (TSC) and in some focal cortical dysplasia (FCD) cases, treatment resistant epilepsy (TRE) is associated with increased activation of mammalian target of rapamycin (mTOR) signaling [1, 2]. This evidence concerns the gene MTOR and fleck corneal dystrophy.